| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0135 |
Injection, adalimumab, 20 mg |
1,696 |
1,377 |
$851K |
| J1438 |
Injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
793 |
645 |
$482K |
| J2357 |
Injection, omalizumab, 5 mg |
835 |
637 |
$444K |
| J3490 |
Unclassified drugs |
1,736 |
1,536 |
$388K |
| J1726 |
Injection, hydroxyprogesterone caproate, (makena), 10 mg |
456 |
338 |
$92K |
| J2182 |
Injection, mepolizumab, 1 mg |
25 |
24 |
$18K |
| J2941 |
Injection, somatropin, 1 mg |
36 |
24 |
$15K |
| J3590 |
Unclassified biologics |
710 |
533 |
$8K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
54 |
51 |
$5K |
| S5000 |
Prescription drug, generic |
51 |
39 |
$3K |
| J8521 |
Capecitabine, oral, 500 mg |
23 |
15 |
$1K |
| Q0511 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period |
296 |
265 |
$234.69 |
| Q0512 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period |
34 |
28 |
$16.20 |